Doxepin
Sinequan
- Dosage form
- Tablet
- Available strengths
- 10 mg, 25 mg, 50 mg, 75 mg, 100 mg
- Drug class
- Tricyclic antidepressant (dibenzoxepine-derivative, with anxiolytic properties)
- Common brand
- Sinequan
Clinical overview. Doxepin, sold under the brand name Sinequan, is a tricyclic antidepressant with anxiolytic and sedative properties used to treat anxiety and depressive conditions, including psychotic depression. It is started at a low dose and titrated upward, with full antidepressant benefit typically taking ten days or more to appear. Because it can affect heart rhythm, cause significant sedation and anticholinergic effects, and is dangerous in overdose, it requires caution in elderly patients and those with cardiovascular disease, and should never be combined with monoamine oxidase inhibitors.
Indication
Common therapeutic uses
- Doxepin is used to treat anxiety and depressive reactions in psychoneurotic patients.
- It is used for anxiety neurosis that occurs together with physical (somatic) symptoms.
- It is used as an adjunct in alcoholic patients who have anxiety and/or depression.
- It is used to treat psychotic depression, including the depressed phase of manic-depressive illness and involutional melancholia.
Pregnancy
Risk assessment and monitoring considerations
- The safety of doxepin during pregnancy has not been established.
- Doxepin should not be used in women who could become pregnant unless the physician determines the potential benefit to the patient outweighs the possible risk to the fetus.
- Discuss any plan to become pregnant, or a suspected pregnancy, with your doctor promptly so the treatment can be reassessed.
Breastfeeding
Infant exposure considerations
- The safety of doxepin during breastfeeding has not been established, and it should not be used by nursing mothers unless the potential benefit outweighs the possible risk to the infant.
- Like other tricyclic antidepressants, doxepin is known to pass into breast milk and has been associated with sedation in breastfed infants.
Geriatrics
Dosing and tolerability considerations
- Doxepin should be used with extreme caution in elderly patients because of their greater vulnerability to cardiovascular side effects; treatment should start with a low dose and increase gradually, with close monitoring.
- Elderly and hospitalized patients are at greater risk of severe constipation and paralytic ileus from doxepin's anticholinergic effects.
Pediatrics
Use in children and adolescents
- Doxepin is not recommended for use in children, since its safety and effectiveness in this age group have not been established.
Dosage & Administration
Practical dosing and administration
- Treatment usually starts at 25 mg three times daily for most adult patients.
- The dose can be increased in 25 mg increments at appropriate intervals until an adequate response is achieved.
- The usual optimal maintenance dose range is 100 to 150 mg per day, though some patients may need up to 300 mg per day, with little added benefit typically seen above this level.
- In elderly patients, dosage increases should proceed more cautiously, starting from a lower initial dose.
- Once a satisfactory response is achieved, the dose can often be reduced while maintaining the therapeutic effect.
- For maintenance therapy, the total daily dose, up to 150 mg, may be given once daily, preferably at bedtime given its sedating effects.
Overdose
Recognizing and responding to overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- Excessive drowsiness leading to altered consciousness or unresponsiveness can be an early sign of doxepin overdose.
- Overdose is more typically marked by increased agitation and convulsions that can progress to slowed breathing and coma.
- Widening of the QRS complex and T-wave abnormalities on the ECG tend to appear later and are not always accompanied by cardiovascular symptoms.
- Cardiac arrhythmias and effects on the central nervous system pose the greatest danger in doxepin overdose and can develop suddenly even when initial symptoms seem mild.
- Management is symptomatic and supportive; if the patient is conscious, induced vomiting followed by gastric lavage with precautions against aspiration, and then activated charcoal, can help reduce further absorption if done soon after ingestion.
- Continuous ECG monitoring in an intensive care setting is recommended, particularly if the QRS interval is prolonged, and should continue for several days because of the risk of delayed cardiac complications.
- Barbiturates should be avoided when treating seizures caused by doxepin overdose, since they can worsen breathing difficulty and low blood pressure.
- Physostigmine given slowly by intravenous injection has been used to reverse cardiovascular and central nervous system anticholinergic effects of tricyclic antidepressant overdose.
Common side effects
Frequently reported tolerability concerns
- Drowsiness or sedation may occur.
- Fatigue may occur.
- Dizziness may occur.
- Dry mouth may occur.
- Blurred vision or other visual disturbances may occur.
- Constipation may occur.
- Nasal stuffiness may occur.
- Nausea or stomach upset may occur.
- Weight gain may occur.
- Increased sweating may occur.
- Headache may occur.
- Difficulty urinating or delayed urination may occur.
Serious side effects
Findings that may require urgent assessment
Serious side effects require immediate discussion with the prescriber or emergency care.
- Seizures may occur, since doxepin, like other tricyclic antidepressants, lowers the seizure threshold.
- Cardiac arrhythmias, heart block, and, rarely, cardiac arrest can occur, especially at higher doses or in patients with existing heart disease.
- Sinus tachycardia and other changes in heart rhythm or conduction can occur.
- Unexpected death has been reported in patients with cardiovascular disease taking tricyclic antidepressants.
- Heart attack and stroke have been reported with this class of medication.
- Activation of latent psychosis, or triggering of manic or hypomanic episodes, can occur, particularly in patients with schizophrenia or bipolar disorder.
- Bone marrow suppression, including agranulocytosis, low white blood cell counts, and low platelet counts, has been reported.
- Severe anticholinergic effects, including paralytic ileus and urinary retention, can occur, particularly in elderly or hospitalized patients.
- Doxepin can precipitate or worsen narrow-angle glaucoma because of its anticholinergic effects.
- Obstructive jaundice and hepatitis have been reported.
- Syndrome of inappropriate antidiuretic hormone secretion, which can cause dangerously low blood sodium, has been reported.
- Tardive dyskinesia and other involuntary movement disorders have been reported.
- The risk of suicidal thoughts or behaviour can persist in severely depressed patients until significant improvement occurs, so close supervision is recommended, especially early in treatment.
- Stopping doxepin abruptly after prolonged use can cause withdrawal-type symptoms such as nausea, headache, and malaise, though these do not indicate addiction.
- Seek urgent medical attention for chest pain, fainting, a fast or irregular heartbeat, a seizure, or severe confusion while taking doxepin.
Use with caution
Situations requiring closer assessment
- Use with extreme caution in patients with cardiovascular disease and in elderly patients, starting with low doses and increasing gradually under close supervision.
- Use with caution in patients with a history of seizure disorders, since tricyclic antidepressants can lower the seizure threshold.
- Use with caution when electroconvulsive therapy is given at the same time as doxepin, since the combination may be hazardous and should be limited to essential cases.
- Use with caution in patients with an overactive thyroid or those taking thyroid medication, because of the risk of cardiovascular toxicity.
- Use with caution in patients also taking guanethidine or related blood pressure medications, since doses of doxepin above 150 mg per day may block their antihypertensive effect.
- Use with caution in patients with impaired liver function or a history of liver damage or blood disorders; periodic blood counts and liver function tests are recommended with high doses or prolonged treatment.
- Use with caution when doxepin is combined with other anticholinergic or sympathomimetic drugs, which requires close supervision and careful dose adjustment.
- Discontinue doxepin before elective surgery for as long as clinically feasible.
- Use with caution in patients with a history of urinary retention or glaucoma-type eye problems.
- Avoid driving or operating machinery requiring alertness until you know how doxepin affects you, since it can cause drowsiness.
- Use with caution when combining doxepin with alcohol or other central nervous system depressants, since their effects may be intensified.
Contraindications
Situations where therapy may be inappropriate
- Contraindicated in patients with known hypersensitivity to doxepin or to other dibenzoxepine compounds.
- Contraindicated in patients with glaucoma or increased pressure in the eye, because of doxepin's anticholinergic activity.
- Contraindicated in patients with urinary retention.
- Contraindicated during the acute recovery phase following a heart attack.
- Contraindicated in patients with acute congestive heart failure.
- Contraindicated in patients with a history of blood disorders.
- Contraindicated in patients with severe liver disease.
- Contraindicated for concurrent use with monoamine oxidase inhibitors, which should be stopped at least two weeks before starting doxepin because of the risk of a severe reaction with intense sympathetic stimulation.
Drug interactions
Clinically relevant combinations
- Combining doxepin with monoamine oxidase inhibitors can cause a dangerous reaction involving intense sympathetic stimulation; MAO inhibitors should be stopped at least two weeks before starting doxepin.
- Alcohol, barbiturates, and other central nervous system depressants can have their effects intensified by doxepin.
- Combining doxepin with other anticholinergic drugs can increase anticholinergic side effects such as dry mouth, blurred vision, constipation, and urinary retention.
- Combining doxepin with sympathomimetic drugs requires close supervision and careful dose adjustment.
- Cimetidine can raise doxepin blood levels and has been linked to serious anticholinergic symptoms such as severe dry mouth, urinary retention, and blurred vision; stopping cimetidine can lower doxepin levels and reduce its effect.
- Drugs that inhibit or are metabolized by the CYP2D6 liver enzyme, such as quinidine and selective serotonin reuptake inhibitors, may raise doxepin blood levels when taken together.
- Doses of doxepin above 150 mg per day may block the blood-pressure-lowering effect of guanethidine and related antihypertensive medications.
- Concurrent electroconvulsive therapy with doxepin may be hazardous and should be limited to cases where it is essential.
Food interactions
Meal-related administration
- Doxepin capsules can be taken with or without food; food does not significantly affect how much of the medicine is absorbed, though taking it with food may help reduce stomach upset in some patients.
Time of administration
Practical scheduling
- For maintenance treatment, the full daily dose is often taken once a day, preferably at bedtime, because of doxepin's sedating effects; during dose titration, it may instead be split into two or three doses through the day as directed, and it can be taken with or without regard to meals.
Storage
Product handling
- Store doxepin capsules at room temperature, between 15°C and 30°C.
Patient take-away
Key counselling points for a quick closing summary
- Doxepin's calming (anxiolytic) effect can start quickly, but its full antidepressant effect usually takes 10 days or longer to develop, so continue taking it as prescribed even if you do not feel better right away.
- Avoid alcohol and be cautious with driving or operating machinery until you know how doxepin affects your alertness and coordination.
- Do not stop taking doxepin suddenly; talk to your doctor about gradually tapering the dose to avoid withdrawal-type symptoms.
References
Source material and product information
For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.